- Home
- PLRX vs HUMA Comparison
PLRX vs HUMA Comparison
Compare PLRX & HUMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PLRX | HUMA |
|---|---|---|
| Founded | 2015 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 93.3M | 236.0M |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | PLRX | HUMA |
|---|---|---|
| Price | $1.26 | $1.18 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 11 | 8 |
| Target Price | $3.79 | ★ $10.13 |
| AVG Volume (30 Days) | 1.9M | ★ 4.3M |
| Earning Date | 11-06-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $1,571,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $731.05 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.10 | $1.09 |
| 52 Week High | $15.00 | $6.77 |
Technical Indicators
Market Signals| Indicator | PLRX | HUMA |
|---|---|---|
| Relative Strength Index (RSI) | 36.15 | 39.37 |
| Support Level | $1.17 | $1.21 |
| Resistance Level | $1.35 | $1.32 |
| Average True Range (ATR) | 0.12 | 0.08 |
| MACD | -0.02 | 0.01 |
| Stochastic Oscillator | 20.10 | 6.43 |
Price Performance
Historical ComparisonAbout PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.
About HUMA Humacyte Inc.
Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.